Octapharma To Build $1.5 Billion Critical Care Manufacturing Facility In South Carolina
Octapharma plans to invest $1.5 billion in its first U.S.-based manufacturing and production facility, creating approximately 1,500 full-time jobs in Rock Hill, South Carolina.
The 50-acre campus will be developed at Palmetto Research Park and is expected to become one of the largest private biomedical investments in South Carolina’s history.
The facility will produce plasma-derived therapies from Octapharma’s portfolio, establishing domestic manufacturing capabilities for medicines currently supported by the company’s international production network.
Octapharma also plans to manufacture bleeding management and trauma care products used for national security and emergency preparedness purposes.
The project is intended to reduce dependence on overseas pharmaceutical supply chains while bringing production closer to the plasma donated in the United States and the American patients who rely on the company’s treatments.
Octapharma selected Rock Hill following a planning and zoning process conducted with Rock Hill and York County officials and in coordination with local, state and federal leaders.
The company cited South Carolina’s advanced manufacturing infrastructure, logistics network, access to deep-water ports and growing biomedical workforce as factors supporting the location decision.
Octapharma expects demand for its existing therapies and future products to increase, requiring the company to expand its manufacturing capacity.
Construction and groundbreaking details will be announced at a later date.
Headquartered in Lachen, Switzerland, Octapharma develops and manufactures human protein therapies derived from human plasma and cell lines. The company has more than 11,000 employees and serves patients in 117 countries across immunotherapy, hematology and critical care.
Octapharma currently operates five European manufacturing facilities, seven research and development sites and more than 200 plasma donation centers across the United States and Europe.
KEY QUOTES:
“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products. Our manufacturing capacity must evolve to support this ambition, and our U.S. manufacturing facility will be an important milestone. From a U.S. national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”
Wolfgang Marguerre, CEO and Chairman of Octapharma
“We have built a significant presence in the U.S. over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centers. As the demand in the U.S. for our portfolio of products continues to grow, the new U.S. manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the U.S. and to the patients who rely on them.”
Tobias Marguerre, Deputy Chairman of Octapharma
“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition. We also want to thank Governor McMaster and South Carolina’s federal and state delegation for their support in welcoming Octapharma to the Palmetto State.”
“South Carolina’s talented workforce, strong life sciences ecosystem and pro-business environment made it clear this was the right home for our first U.S. manufacturing facility.”
Flemming Nielsen, President of Octapharma USA
